Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1945 1
1950 1
1951 2
1954 2
1955 2
1956 2
1957 1
1958 3
1961 5
1962 2
1963 3
1964 3
1965 2
1966 1
1967 8
1968 6
1969 2
1970 12
1971 7
1972 7
1973 6
1974 4
1975 6
1976 8
1977 7
1978 4
1979 8
1980 4
1981 7
1982 4
1983 2
1984 2
1986 4
1988 6
1989 4
1990 7
1991 2
1992 4
1993 1
1994 1
1995 5
1996 2
1997 1
1998 4
1999 1
2000 1
2001 3
2002 3
2003 4
2004 2
2005 4
2006 6
2007 10
2008 11
2009 9
2010 14
2011 16
2012 12
2013 13
2014 19
2015 20
2016 28
2017 13
2018 22
2019 19
2020 17
2021 23
2022 29
2023 25
2024 21
2025 26
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

512 results

Results by year

Filters applied: . Clear all
Page 1
Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N. Shattock AJ, et al. Among authors: white rg. Lancet. 2024 May 25;403(10441):2307-2316. doi: 10.1016/S0140-6736(24)00850-X. Epub 2024 May 2. Lancet. 2024. PMID: 38705159 Free PMC article.
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M; CORTIS-01 Study Team. Scriba TJ, et al. Among authors: white rg. Lancet Infect Dis. 2021 Mar;21(3):354-365. doi: 10.1016/S1473-3099(20)30914-2. Epub 2021 Jan 25. Lancet Infect Dis. 2021. PMID: 33508224 Free PMC article. Clinical Trial.
Reply to McShane.
Hill PC, Cobelens F, Martinez L, Garcia-Basteiro AL, Behr MA, Rangaka MX, Churchyard G, Evans T, Hanekom W, White RG. Hill PC, et al. Among authors: white rg. J Infect Dis. 2024 Feb 14;229(2):616. doi: 10.1093/infdis/jiad466. J Infect Dis. 2024. PMID: 37897697 Free PMC article. No abstract available.
Implications of subclinical tuberculosis for vaccine trial design and global effect.
Churchyard GJ, Houben RMGJ, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG. Churchyard GJ, et al. Among authors: white rg. Lancet Microbe. 2024 Oct;5(10):100895. doi: 10.1016/S2666-5247(24)00127-7. Epub 2024 Jul 1. Lancet Microbe. 2024. PMID: 38964359 Free PMC article. Review.
Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys.
Emery JC, Dodd PJ, Banu S, Frascella B, Garden FL, Horton KC, Hossain S, Law I, van Leth F, Marks GB, Nguyen HB, Nguyen HV, Onozaki I, Quelapio MID, Richards AS, Shaikh N, Tiemersma EW, White RG, Zaman K, Cobelens F, Houben RMGJ. Emery JC, et al. Among authors: white rg. Elife. 2023 Dec 18;12:e82469. doi: 10.7554/eLife.82469. Elife. 2023. PMID: 38109277 Free PMC article. Review.
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data.
Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C, Aronson NE, Bonnet M, Carvalho AC, Chan PC, Huang LM, Fang CT, Churchyard G, Corral-Londoño HD, Datta M, Espinal MA, Fielding K, Fiore-Gartland AJ, Garcia-Basteiro A, Hanekom W, Hatherill M, Hill PC, Huerga H, Jones-López EC, Kritski A, Mandalakas AM, Mangtani P, Martins Netto E, Mayanja H, Mazahir R, Murray M, Rangaka M, Scriba T, Singh J, Singh S, Stein CM, Vekemans J, Verhagen LM, Villalba JA, Wajja A, Watson B, White RG, Cobelens FGJ. Pelzer PT, et al. Among authors: white rg. Lancet Microbe. 2025 Feb;6(2):100961. doi: 10.1016/j.lanmic.2024.100961. Epub 2024 Dec 19. Lancet Microbe. 2025. PMID: 39709975 Free PMC article.
An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials.
Hill PC, Cobelens F, Martinez L, Behr MA, Churchyard G, Evans T, Fiore-Gartland AJ, Garcia-Basteiro AL, Hanekom W, Rangaka MX, Vekemans J, White RG. Hill PC, et al. Among authors: white rg. J Infect Dis. 2023 Nov 2;228(9):1150-1153. doi: 10.1093/infdis/jiad356. J Infect Dis. 2023. PMID: 37607272
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials.
White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, Cobelens F, Ernst JD, Esmail H, Garcia-Basteiro AL, Hadinegoro SR, Hanekom WA, Hatherill M, Hill PC, Muloiwa R, Pelzer PT, Rangaka L, Rees H, Schrager L, Stanley M, Tufet M, Wong EB, Houben RMGJ. White RG, et al. Lancet Respir Med. 2025 Oct;13(10):933-942. doi: 10.1016/S2213-2600(25)00164-X. Epub 2025 Jul 3. Lancet Respir Med. 2025. PMID: 40618773 Free PMC article. Review.
The way forward for tuberculosis vaccines.
White RG, Hanekom WA, Vekemans J, Harris RC. White RG, et al. Lancet Respir Med. 2019 Mar;7(3):204-206. doi: 10.1016/S2213-2600(19)30040-2. Lancet Respir Med. 2019. PMID: 30823973 No abstract available.
512 results